Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
We pick out particular compounds from an extensive virtual database of more than 60 billion molecules. The preparation and shipment of these compounds are facilitated by our associate Reaxense.
The library includes a list of the most promising modulators annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Also, each compound is presented with its optimal docking poses, affinity scores, and activity scores, providing a comprehensive overview.
We use our state-of-the-art dedicated workflow for designing focused libraries.
Fig. 1. The sreening workflow of Receptor.AI
By deploying molecular simulations, our approach comprehensively covers a broad array of proteins, tracking their flexibility and dynamics individually and within complexes. Ensemble virtual screening is utilised to take into account conformational dynamics, identifying pivotal binding sites located within functional regions and at allosteric locations. This thorough exploration ensures that every conceivable mechanism of action is considered, aiming to identify new therapeutic targets and advance lead compounds throughout a vast spectrum of biological functions.
Our library distinguishes itself through several key aspects:
partner
Reaxense
upacc
P60006
UPID:
APC15_HUMAN
Alternative names:
-
Alternative UPACC:
P60006; G3V1Q3; Q9CXK2; Q9Y269
Background:
Anaphase-promoting complex subunit 15 is a crucial component of the APC/C, a cell cycle-regulated E3 ubiquitin ligase. It plays a pivotal role in mitosis and G1 phase progression, specifically in the release of the MCC from the APC/C. This action is vital for the spindle assembly checkpoint's responsiveness, through promoting the turnover of CDC20 and MCC.
Therapeutic significance:
Understanding the role of Anaphase-promoting complex subunit 15 could open doors to potential therapeutic strategies.